TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering. Shares were trading around $3.58. The stock is down about 50% on the year.

Clinical-stage biotechnology company TScan Therapeutics, Inc. (TCRX) Thursday announced that it has entered into a securities ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027 ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for ...

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded warrants ...

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, announced ...

Gordon Brothers in a joint venture with Hilco Consumer - Retail and Tiger Capital Group, began store closing sales at all 869 Big Lots locations. The U.S. closeout retailer is offering up to 25% off ...

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.

Shares of TCRX opened at $3.02 on Wednesday. TScan Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a ...